ALPHARETTA, Ga., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that results from their Phase 2 clinical trial (DOGWOOD) and Phase 1/2 clinical trial for the treatment of macular edema associated with non-infectious uveitis will be presented at the 2016 Annual Meeting of the American Society of Retina Specialists (ASRS), August 9-14, 2016, in San Francisco, CA.
Steven Yeh, MD, Louise M. Simpson Professor of Ophthalmology and Uveitis and Vitreoretinal Surgery Director, Uveitis and Vasculitis Service at the Emory Eye Center, Emory University, will present:
- Suprachoroidal Administration of Triamcinolone Acetonide: Results of a Phase 2 Study of Patients with Non-infectious Uveitis. [August 14, 9:04 a.m.]
Seenu Hariprasad, MD, Shui-Chin Lee Professor of Ophthalmology and Visual Science, Chief, Vitreoretinal Service and Director of Clinical Research at the University of Chicago Department of Ophthalmology and Visual Science, will present:
- Suprachoroidal Administration of Triamcinolone Acetonide: Combined Results of Phase 1/2 and Phase 2 Clinical Studies. [August 14, 9:53 a.m.]
Shree K. Kurup, MD, Retina Center Tucson (AZ), former Professor, Director Medical Retina and Vitreoretinal Surgery and Research at the Kansas University Eye Center, University of Kansas and former Associate Professor, Surgical Sciences, Bowman Gray School of Medicine at Wake Forest University, will present:
- Treatment of Uveitic Macular Edema with Corticosteroids Utilizing a Novel Approach: Suprachoroidal Injector. [August 14, 10:01 a.m.]
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a publicly-traded, late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside’s proprietary suprachoroidal space microinjector to reach diseased tissue through the suprachoroidal space. Clearside holds intellectual property protecting the delivery of drugs of any type through the suprachoroidal space to reach the back of the eye. Clearside has a portfolio of clinical and pre-clinical programs using drug administration through the suprachoroidal space to provide a route of access to treat diseases of the back-of-the-eye such as retinal vein occlusion (RVO), uveitis, neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Clearside is currently enrolling patients in a Phase 3 clinical trial (PEACHTREE) for the treatment of patients with macular edema associated with non-infectious uveitis and has initiated IND-enabling studies for the treatment of wet AMD. Visit www.clearsidebio.com for more information.